Trials / Recruiting
RecruitingNCT07005284
A Study of LY3981314 in Healthy Participants
A Single-Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of LY3981314 in Healthy Participants
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 76 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to investigate the safety of LY3981314 when administered subcutaneously (SC) (under the skin), and how it's processed in the body. The study will last approximately 25 weeks, excluding a screening period with an optional extension to approximately 49 weeks for qualifying participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3981314 | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2025-06-09
- Primary completion
- 2027-02-01
- Completion
- 2027-02-01
- First posted
- 2025-06-05
- Last updated
- 2025-09-25
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07005284. Inclusion in this directory is not an endorsement.